Eli Lilly to Acquire Merida Biosciences for Up to $2.875B in Cash
LLY sits 63% above its 52-week low of $712.05.
Summary
Eli Lilly agreed to acquire biotech firm Merida Biosciences for up to $2.875 billion in cash, expanding its immunology portfolio. The deal adds a new pipeline asset and follows a string of positive clinical and financial developments for Lilly, including strong Q2 revenue growth and FDA approval of Foundayo. The acquisition is material but modest relative to Lilly's market cap, and the cash outlay is manageable given its robust balance sheet. The biotech ETF rose on the news, signaling broader sector optimism about deal activity. Watch for further details on Merida's lead candidates and expected closing timeline.
At the time of this announcement, LLY was trading at $1,159.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.